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Emerging evidence has indicated a role of the bone morphoge-
netic proteins (BMP) in the pathogenesis of certain cancers. The
signaling of BMP family members is tightly regulated by their
antagonists, including noggin and SOST, which are, in turn, posi-
tively regulated by BMP, thereby forming a negative feedback
loop. Consequently, the expression of these antagonists should
be taken into account in studies on the prognostic significance of
BMP. In the present paper, we correlated protein and mRNA
expression levels of BMP6, noggin and SOST, alone or in combi-
nation, with patient survival in various types of cancer. We found
that BMP6 alone was not significantly correlated with esophageal
squamous cell carcinoma patient survival. Instead, a high level of
inhibitor of differentiation 1, a downstream factor of BMP6, was
associated with shorter survival in patients whose tumors stained
strongly for BMP6. Knockdown of noggin in esophageal cancer
cell line EC109, which expresses BMP6 strongly and SOST weakly,
enhanced the non-adherent growth of the cells. Noggin and
SOST expression levels, when analyzed alone, were not signifi-
cantly correlated with patient survival. However, high BMP6
activity, defined by strong BMP6 expression coupled with weak
noggin or SOST expression, was significantly associated with
shorter survival in esophageal squamous cell carcinoma patients.
We further confirmed that BMP6 activity could be used as a prog-
nostic indicator in prostate, bladder and colorectal cancers, using
publicly available data on BMP6, noggin and SOST mRNA expres-
sion and patient survival. Our results strongly suggest that
BMP6, noggin and SOST could be used in combination as a prog-
nostic indicator in cancer progression. (Cancer Sci 2012; 103:
1145–1154)
D espite the fact that the 5-year survival rate for esophagealcancer improved from 5% to 19% in the USA between
1975 and 2005, survival is still poor relative to common can-
cers originating from other sites.(1) The predominant subtype
of esophageal cancer in Asian countries is esophageal squa-
mous cell carcinoma (SCC),(2) which has a poor prognosis.(3)
Attempts are being made to identify environmental and genetic
susceptibility factors of esophageal SCC.(4–6) In addition, the
molecular basis of esophageal SCC progression is still largely
unknown.
The bone morphogenetic proteins (BMP) are family mem-
bers of the TGF-b superfamily of cytokines, whose first identi-
fied function was the promotion of bone formation. The
activity of BMP is marshaled by their intrinsic antagonists,
which include noggin and SOST.(7) BMP signaling plays an
important role in the normal development of the esophagus;
dysregulation of BMP and their native antagonists can result in
improper development of the esophagus in the embryonic
stage.(8–10) Altered expression of BMP also results in an
inflammatory response in the esophagus,(11,12) as well as onset
of Barrett’s esophagus, a premalignant lesion of esophageal
adenocarcinoma.(13) The significance of BMP6 in esophageal
SCC was revealed when a high level of BMP6 expression was
correlated with shorter survival.(14) Moreover, BMP6 is upreg-
ulated in prostate cancer,(15,16) clear cell renal carcinoma(17)
and osteosarcoma.(18)
Bone morphogenetic proteins regulate the expression of
inhibitor of differentiation (Id) proteins in various cellular con-
texts.(19–21) We have previously shown that Id-1 is overexpres-
sed in esophageal SCC, and its expression is an independent
predictor of shorter survival.(22) BMP activate Smad1/5/8 phos-
phorylation, which leads to translocation of Smad4 into the
nucleus, thereby activating the transcription of Id proteins in a
Smad-dependent manner.(23–26) However, the relationship
between Id proteins and BMP in esophageal SCC is not
known.
In the present study, we investigate the role of BMP6 in
esophageal SCC development and progression, and examine
whether BMP6 and its antagonists, noggin and SOST, or
downstream effectors, such as Id-1 and pSmad1/5/8, are asso-
ciated with patient survival.
Materials and Methods
Patients and specimens. Patient data and specimens were col-
lected and described previously,(22) and are summarized in
Table 1.
Immunohistochemical staining. Immunohistochemical staining
for Id-1 in the same cohort was performed previously.(22) The
staining of BMP6, noggin and SOST was performed as previ-
ously described.(15) Staining of phospho-Smad1/5/8 was per-
formed as previously described using pSmad1/5/8 antibody at
a concentration of 1:100 (Cell Signaling, Danvers, MA, USA;
Cat. no. 9511).
Evaluation of immunohistochemical staining results. The
stained sections were reviewed by two independent observers
(KWC and YPC), who had no prior knowledge of the clinic-
pathological data of the patients. All three cores of the same
specimens were scored independently and the highest score
among the three cores was used for later statistical analysis. In
the survival analyses, strong expression of BMP6 was stratified
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as high level staining, while weak to moderate expression of
BMP6 was stratified as low level staining. The staining of nog-
gin, SOST and pSmad1/5/8 was evaluated as for BMP6. Speci-
mens were further stratified into two groups based on their
expression levels of all of BMP6, noggin and SOST. Those
stained with a high level of BMP6, and low levels of both
noggin and SOST were classified as having high BMP6 activ-
ity; patterns other than that were classified as having low
BMP6 activity, as previously described.(15) The staining of Id
proteins was evaluated previously.(22)
Statistical analysis. Statistical analysis was performed using
IBM SPSS 19.0 (Armonk, NY, USA). The significance of the
differences in the protein expression levels between normal
epithelium and esophageal SCC specimens was analyzed by
chi-square-test. Correlations between expression levels of dif-
ferent proteins and stages of the disease were analyzed by
Spearman’s rank correlation test. Kaplan–Meier analysis was
performed using either log-rank or Wilcoxon–Gehan tests. Cox
regression was performed with forward conditional stepwise
selection with an inclusion value of P < 0.05. The differences
between groups were compared using Student’s t-test.
P < 0.05 was considered statistically significant in all tests.
Cell lines. Immortalized esophageal epithelial cell line NE1
was maintained in keratinocyte serum-free medium (KSFM)
(Invitrogen, Paisley, UK). Esophageal SCC cell lines HKESC-1,
HKESC-2 and HKESC-3 were maintained in alpha-MEM sup-
plemented with 10% FBS. Esophageal SCC cell lines SLMT-1,
EC1, EC109 and EC18 were maintained in RPMI1640 supple-
mented with 10% FBS. Viral packaging cell line 293T was
maintained in DMEM supplemented with 10% FBS. Stable
EC109 shScr, shNOG-1 and shNOG-2 cells were generated by
lentiviral infection of pLKO.1 plasmid expressing scramble
shRNA (Addgene ID: 17920, a gift from Professor SA Stewart),
noggin shRNA1 (obtained from Sigma [St. Louis, MA, USA],
ID NM_005450.2-452s1c1) and noggin shRNA2 (Sigma ID:
NM_005450.2-676s1c1). Stably infected cells, selected using
puromycin and having undergone fewer than 10 passages, were
used for all assays performed in the present study.
Reverse transcription quantitative PCR. RNA was extracted
using Trizol (Invitrogen) and was reverse transcribed using the
Superscript III first-strand synthesis system (Invitrogen)
according to the manufacturer’s instructions. Quantitative PCR
was performed using Taqman gene expression assays
(Invitrogen) for BMP6 (ID: Hs01099594_m1), noggin (ID:
Hs00271352_s1) and SOST (ID: Hs00228830_m1) according
to the manufacturer’s instructions.
Western blot analysis. Western blotting was performed as
previously described. BMP6 (R&D system, Minneapolis, MN,
USA) and noggin (Abcam, Cambridge, UK) antibodies were
used at concentrations of 0.5 and 2.5 lg/mL, respectively.
Phospho-Smad1/5/8 antibody (Cell Signaling Technology) and
actin antibody (Sigma) were used at dilutions of 1:1000 and
1:10 000, respectively.
Colony formation assay. A total of 500 EC109 cells were
seeded in a six-well plate and allowed to grow for 2 weeks.
The cells were fixed with 70% ethanol and the colonies were
stained with 0.1% crystal violet. The plates were photographed
and colonies formed were enumerated.
Soft agar assay. EC109 cell suspension in culture medium
containing 0.35% (w/v) low melting point agarose (Invitrogen)
were overlaid on a base layer of solidified culture medium that
contained 0.7% (w/v) low melting point agarose. The mixture
was allowed to solidify and was incubated at 37°C for
3 weeks. A few drops of medium were added every 2 days.
The plates were photographed and the colonies formed were
enumerated.
Analysis of cancer patient microarray data. A prostate cancer
patient dataset (GSE 21035),(27) a bladder cancer dataset (GSE
13507)(28) and three colorectal cancer datasets (GSE 14333,(29)
GSE 17536 and GSE 17537)(30) (the only available carcinoma
patient datasets in the Gene Expression Omnibus database of
the Prognoscan platform(31) with microarray data for
BMP6, noggin and SOST, as well as survival data) were inves-
tigated. The datasets were pre-processed as previously
described.(32)
Results
Bone morphogenetic protein 6 expression in esophageal squa-
mous cell carcinoma. Here, by reverse transcription quantitative
PCR, we found that BMP6 was significantly overexpressed in
six out of seven esophageal SCC cell lines compared to the
immortalized non-transformed esophageal epithelial cell line
NE1 (Fig. 1A). Similarly, we also observed an increase in
BMP6 protein level by western blot in esophageal SCC cell
lines compared to NE1 cells (Fig. 1B). Immunohistochemical
staining of 84 human esophageal SCC and 33 non-tumor
esophageal epithelium specimens revealed that BMP6 was
either moderately or strongly expressed in 76 out of 80 esoph-
ageal SCC specimens (Fig. 1C), which is in line with the pre-
vious report showing that BMP6 was expressed in the majority
of the esophageal SCC specimens.(14) The expression level of
BMP6 was significantly lower in non-tumor esophageal epithe-
lium compared to the esophageal SCC specimens (v2-test,
P < 0.001), with only 7 out of 32 non-tumor specimens having
moderate or strong staining of BMP6 (Fig. 1D). However, the
association between BMP6 protein expression and survival
was not statistically significant (log-rank test, P = 0.288).
Significance of inhibitor of differentiation 1 expression in bone
morphogenetic protein 6-high tumors. Bone morphogenetic pro-
tein 6 and Id-1 expression levels were found to be significantly
positively correlated in the esophageal SCC specimens in our
current cohort (Spearman’s rank test, r = 0.227, P = 0.046;
Fig. 2A). BMP6 expression was also significantly correlated
with Id-3 expression (Spearman’s rank test, r = 0.324,
P = 0.005; Fig. 2C). Conversely, BMP6 expression did not
correlate with that of Id-2 (Spearman’s rank test, r = 0.165,
P = 0.147; Fig. 2B). More importantly, we found that a low
Table 1. Patient clinical and pathologic features
Number of cases % Median (range)
Age 81 67 (41–87) years
Sex
Male 62 77
Female 19 24
T-stage
T1 2 3
T2 13 16
T3 49 61
T4 17 21
N-stage
N0 30 37
N1 51 63
M-stage
M0 68 84
M1 13 16
pTNM staging
Stage II 32 40
Stage III 36 44
Stage IV 13 16
Histological grade
Well-differentiated 13 16
Moderately-differentiated 48 59
Poorly-differentiated 20 25
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level of Id-1 expression was associated with longer survival in
patients whose tumors stained strongly for BMP6 (Wilcoxon–
Gehan test, P = 0.042; Fig. 2D). As Id-1 expression is con-
trolled by BMP6-activated Smad,(20,24) this result provides
indirect evidence that tumors with higher levels of BMP6 can
be divided into two distinct groups that differ in their degrees
of aggression based on Id-1 expression. Tumors that translate
a high level of BMP6 to transactivate its downstream target
Id-1 are more aggressive than those whose BMP6 signaling is
interrupted and cannot affect Id-1 activation.
Knockdown of noggin in EC109 cells reduces their non-adher-
ent growth. BMP6 has upregulates expression of noggin and
SOST to form a negative feedback loop,(33,34) in which noggin
and SOST inhibit BMP6.(35,36) Noggin mRNA was overexpres-
sed in six out of seven esophageal SCC cell lines (Fig. 3A),
while SOST mRNA was overexpressed in four out of seven
esophageal SCC cell lines (Fig. 3B) compared to NE1 cells.
All seven cell lines overexpressed at least one BMP6 antago-
nist. We also found that noggin mRNA levels were positively
correlated with BMP6 mRNA levels in the eight esophageal
cell lines (Spearman’s rank test, r = 0.81, P = 0.015), suggest-
ing that BMP6 and noggin are co-expressed in esophageal cell
lines. We investigated the biological implications of uncou-
pling this co-expression in EC109 cells, which express a high
level of BMP6 and noggin, and a low level of SOST. Knock-
down of noggin in EC109 cells, by shNog-1 shRNA, resulted
in a reduced expression of noggin at the protein level and a
concomitant increase in phospho-Smad1/5/8 (pSmad, Fig. 3C),
and this occurred independent of the presence or absence of
serum (Fig. 3D). The consequential increase in BMP signaling
activity in turn resulted in a significant increase in non-adher-
ent growth of the cells (Fig. 3E). This increase in non-adherent
growth cannot be explained by an increase in proliferation rate
as noggin knockdown did not significantly affect the 2-D col-
ony formation ability of the cells (Fig. 3E). These biological
implications of noggin interference were mirrored in parallel
experiments using a second shRNA sequence targeting noggin
(Fig. 3F,G).
Significance of noggin and SOST expression in esophageal
squamous cell carcinoma expressing high levels of BMP6. Noggin
(v2-test, P < 0.001; Fig. 4A,B) and SOST (v2-test, P < 0.001,
Fig. 4C,D) were overexpressed in esophageal SCC specimens
compared to non-tumor esophageal epithelium. This is in
accordance with the esophageal cell line studies, when both
proteins were overexpressed in transformed cell lines com-
pared to an immortalized cell line. In the entire esophageal
SCC patient cohort, neither noggin nor SOST expression levels
were significantly correlated with patient survival (Wilcoxon–
Gehan test: P = 0.665 and P = 0.634 for noggin and SOST,
respectively).
Low level expression of SOST was associated with shorter
survival in patients with high BMP6, but not in patients with
low BMP6 (Wilcoxon–Gehan test, P = 0.024 and P = 0.195,
respectively; Fig. 4E,F). The expression level of noggin was
not significantly associated with patient survival either in the
high or low BMP6 patient group. When both BMP antagonists
were considered in tandem, we found that the expression of
both noggin and SOST at low levels was associated with sig-
nificantly shorter patient survival in the high BMP6 sub-group
of patients, but, once again, not in the low BMP6 sub-group
(Wilcoxon–Gehan test: P = 0.021 and P = 0.355, respectively;
Fig. 4G,H). These results suggest that the expression of noggin
and SOST is an important prognostic indicator in patients
whose tumors strongly express BMP6, and further supports the
hypothesis that unchecked BMP6 activity worsens the progno-
sis of esophageal SCC patients.
Prognostic significance of bone morphogenetic protein 6 activ-
ity in esophageal squamous cell carcinoma. Based on BMP6,
noggin and SOST expression, patients can be assigned as hav-
ing high or low BMP6 activity. Patients with high BMP6
activity had a mean survival time of 8.4 months (95% confi-
dence interval [CI] = 2.7–14.1), whereas patients with low
(A) (B)
(C) (D)
Fig. 1. Expression of bone morphogenetic protein 6 (BMP6) in esophageal squamous cell carcinoma (SCC) cell lines and human specimens. (A)
mRNA expression of BMP6 in normal esophageal cell line NE1 and seven oesophageal SCC cell lines. (B) Corresponding protein expression of
BMP6 in esophageal cell lines. (C) Representative images of immunohistochemical staining of BMP6 in human esophageal SCC patients. (D) Histo-
gram showing the percentage of cases with various levels of BMP6 immunohistochemical staining.
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BMP6 activity had a significantly longer (Wilcoxon–Gehan
test, P = 0.002) mean survival time of 22.4 months (95%
CI = 17.6–27.2) (Fig. 4I). By Cox-regression analysis, we
further found that high BMP6 activity (P = 0.014) and higher
T-stage (P = 0.002) were independent predictors of shorter
survival in our patient cohort (Table 2).
Prognostic significance of pSmad1/5/8 expression in esopha-
geal squamous cell carcinoma. We also investigated whether
pSmad1/5/8 expression level is correlated with BMP6 activity
or prognosis of our patient cohort. Indeed, in the esophageal
SCC specimens, pSmad1/5/8 expression level did not signifi-
cantly correlate with BMP6 activity (P > 0.05). This result
suggests that pSmad1/5/8 might not directly reflect the activity
of the BMP6 pathway, as phosphorylation of Smad1/5/8 is also
controlled by other BMP and TGF-b. This indicates that in
esophageal SCC specimens, pSmad1/5/8 expression alone can-
not be used as a surrogate of BMP6 activity. Nonetheless, high
level expression of pSmad1/5/8 is significantly correlated with
a shorter survival time of esophageal SCC patients (P = 0.001;
Fig. 5A,B). In contrast to Id-1 and BMP6 antagonists,
pSmad1/5/8 expression level correlated with survival of esoph-
ageal SCC patients, regardless of BMP6 expression status
(P < 0.05; Fig. 5C,D).
Bone morphogenetic protein 6, noggin and SOST mRNA can
also be used in combination for predicting prognosis in patients
with prostate, colorectal and bladder cancers. We further exam-
ined DNA microarray datasets that comprised 198 prostate
cancer patients, 458 colorectal cancer patients and 165 bladder
cancer patients. mRNA expression levels of BMP6, noggin
and SOST were analyzed along with survival status, and corre-
lations between expression levels and patient survival were
investigated. As shown in Figure 6, none of BMP6 (Fig. 6A),
noggin (Fig. 6B) or SOST (Fig. 6C) mRNA expression levels
alone were significantly associated with patient survival. Nog-
gin mRNA expression was not significantly associated with
patient survival in either BMP6-low (Fig. 6D) or BMP6-high
(Fig. 6E) patients. In contrast, SOST mRNA expression,
although not significantly associated with survival in patients
expressing low levels of BMP6 (Fig. 6F), was significantly
associated with a shorter survival time in BMP6-high patients
(P = 0.046; Fig. 6G). Expression levels of noggin and SOST
were not associated with patient survival in BMP6-low patients
(Fig. 6H), while low level expression of both noggin and
SOST were significantly associated with a shorter survival
time in BMP6-high patients (P = 0.003; Fig. 6I). As with the
esophageal SCC cohort, we attempted to delineate the influ-
ence of BMP6 activity on the survival of our prostate cancer
cohort. As before, prostate cancer patients with high BMP6
activity had a significantly shorter survival time than those
with low BMP6 activity (P = 0.009; Fig. 6J).
Similar results were obtained using datasets from colorectal
and bladder cancers. Colorectal cancer patients whose primary
tumors express high BMP6 activity had a significantly shorter
survival time compared to those whose primary tumors express
(A)
(B)
(C)
(D)
Fig. 2. The correlation between bone morphogenetic protein 6 (BMP6) and Id protein expression and patient survival. (A) The association
between protein expression levels of BMP6 and inhibitor of differentiation (Id)-1 in esophageal squamous cell carcinoma (SCC) patients. (B) The
association between protein expression levels of BMP6 and Id-2 in esophageal SCC patients. (C) The association between protein expression levels
of BMP6 and Id-3 in esophageal SCC patients. (D) Kaplan–Meier analysis for Id-1 expression levels in BMP6-high esophageal SCC patients.
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low BMP6 activity (P = 0.033; Fig. 7A). Bladder cancer
patients who express high levels of BMP6 activity had a
significantly shorter overall survival (P = 0.031; Fig. 7B) and
disease-specific survival (P = 0.046; Fig. 7C) compared to
patients who express low levels of BMP6 activity.
Discussion
The BMP protein family consists of more than 20 members.
They can play positive and negative roles in cancer progression,
depending on the family member and the site of disease.(37–39)
BMP6 has been shown to be overexpressed in esophageal SCC,
and high level expression of BMP6 has been correlated with
shorter patient survival.(14) However, the expressions of noggin
and SOST, BMP6-inducible BMP6 antagonists, were not inves-
tigated in those studies, so the activity of BMP6 was not under-
stood. In the present study, we have demonstrated that
expression levels of noggin and SOST were correlated with sur-
vival in patients with BMP6-high tumors. In addition, BMP6
activity, which is determined by the expression levels of BMP6
(A) (B)
(C) (E)
(F) (G)
(D)
Fig. 3. Role of noggin expression in esophageal squamous cell carcinoma (SCC) cell lines. (A) Expression of noggin mRNA in esophageal SCC cell
lines. (B) Expression of SOST mRNA in esophageal SCC cell line. (C) Protein expression of noggin, BMP6, pSMAD and actin in EC109 shScr and
EC109 shNoggin-1 cells. (D) Expression of pSMAD in EC109 shScr and EC109 shNoggin-1 cells in the absence or presence of serum. (E) The ability
of EC109 shScr and EC109 shNoggin-1 cells to form colonies in 2-D culture and 3-D soft agar. (F) Protein expression of noggin, pSMAD and actin
in EC109 shScr and EC109 shNoggin-2 cells. (G) The ability of EC109 shScr and EC109 shNoggin-2 cells to form colonies in 2-D culture and 3-D soft
agar.
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(A) (C)
(B) (D)
(E) (F)
(G) (H)
(I)
Fig. 4. Immunohistochemical staining of noggin and SOST in esophageal squamous cell carcinoma (SCC) patient specimens and Kaplan–Meier
analysis of the esophageal SCC patient cohort. (A) Representative images of immunohistochemical staining of noggin. (B) Percentage of cases
with various immunohistochemical staining levels of noggin. (C) Representative images of immunohistochemical staining of SOST. (D) Percentage
of cases with various immunohistochemical staining levels of SOST. (E) Low levels of expression of SOST were significantly associated with a
shorter survival time of esophageal SCC patients expressing high levels of bone morphogenetic protein 6 (BMP6) (F) but not in patients express-
ing low levels of BMP6. (G) Low level expressions of both noggin and SOST were significantly associated with a shorter survival time of esopha-
geal SCC patients expressing high levels of BMP6 (H), but not in patients expressing low levels of BMP6. (I) High BMP6 activity was significantly
associated with a shorter survival time in the whole esophageal SCC patient cohort.
1150 doi: 10.1111/j.1349-7006.2012.02252.x
© 2012 Japanese Cancer Association
itself, as well as its intrinsic antagonists, including noggin and
SOST, was an independent predictor of survival in our esopha-
geal SCC patient cohort. As BMP6 activates its two antagonists,
thereby generating another level of regulation in its signal trans-
duction, we speculate that both the overexpression of BMP6 and
the uncoupling of the regulation of its antagonists are required
for esophageal SCC progression in a BMP6-dependent fashion.
Indeed, by using public data on prostate, colorectal and bladder
cancer, we found that BMP6 activity could be a prognostic
indicator for patient survival in multiple malignancies.
Previous studies have indicated that BMP6 is upregulated in
clear cell renal carcinoma(17) and osteosarcoma,(18) but in nei-
ther case was it correlated with progression of the tumors. The
results we present here indicate that BMP6 antagonists should
be included in expression profiling to determine the intrinsic
biological activity of BMP6 in patients, rather than simply
determining BMP6 expression alone. Activation of Smad-1, a
downstream factor of BMP and TGF-b, has been shown to
correlate with poor prognosis in several cancer types,(40) sug-
gesting that the transmission of the upstream ligand-receptor
binding to the downstream signaling pathway might be
an important determinant of cancer progression. Indeed, our
in vitro analysis in the EC109 cells showed that knockdown of
noggin resulted in Smad activation, which implies that BMP
signaling can be activated by interfering with the expression of
its antagonist.
Bone morphogenetic protein signaling was recently sug-
gested to play an important role in stem cell biology.(41) BMP
activate Id proteins via Smad signaling to maintain the self-
renewal ability of mouse embryonic stem cells.(42) In the pre-
sent study, an increase in BMP signaling led to an increase
in Id proteins, thereby enhancing the aggressiveness of can-
cers through dedifferentiation and increased stem cell-like
Table 2. Cox regression analyses of overall survival of esophageal
squamous cell carcinoma patients
Clinical-
pathological
parameters
Univariate analysis Multivariate analysis
RR (95% CI) P RR (95% CI) P
M-stage 2.077 (1.089–3.960) 0.026
T-stage 1.882 (1.232–2.875) 0.003 2.018 (1.281–3.179) 0.002
High BMP6,
low sclerostin
2.303 (1.110–4.780) 0.025
High BMP6,
low noggin
and
sclerostin
2.824 (1.107–7.209) 0.030 3.271 (1.273–8.408) 0.014
BMP6, bone morphogenetic protein 6; CI, confidence interval; RR,
relative risk.
(A)
(C)
(B)
(D)
Fig. 5. Expression and prognostic significance of pSmad1/5/8 in esophageal squamous cell carcinoma (SCC) patients. (A) Representative images
of immunohistochemical staining of pSmad1/5/8 in human esophageal SCC patients. (B) Kaplan–Meier analysis for pSmad1/5/8 expression in
esophageal SCC patients. (C) Kaplan–Meier analysis for pSmad1/5/8 expression levels in bone morphogenetic protein 6 (BMP6)-high esophageal
SCC patients. (D) Kaplan–Meier analysis for pSmad1/5/8 expression levels in BMP6-low esophageal SCC patients.
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properties of the tumor cells. In this study, we found that the
expression of BMP6 and Id-1 were significantly positively cor-
related in our tumor specimens, while Id-1 expression was cor-
related with survival in patients with high-BMP6 tumors. We
and others have previously shown that Id-1 promotes esopha-
geal SCC progression and is overexpressed in human esopha-
geal SCC.(22,43,44) Our results indicate that Id-1 might also be
a downstream effector of BMP6 signaling in esophageal SCC,
thereby promoting cancer progression. In contrast, although
pSmad1/5/8 expression correlated with patient survival in our
esophageal SCC patient cohort, pSmad1/5/8 expression did not
correlate with BMP6 activity in the esophageal SCC speci-
mens, suggesting that pSmad1/5/8 expression cannot replace
BMP6 activity for cancer prognostication.
This study on BMP6, noggin and SOST in esophageal SCC,
as with our previous study of the same factors in prostate can-
cer,(15) has highlighted the importance of considering function-
ally related proteins in a signaling pathway (i.e. positive and
negative regulators) simultaneously for the prognosis of cancer
patients. A combinatorial use of several cooperating factors
might be more useful in predicting cancer progression and
patient survival than individual use of the same factors. Most
notably, our results show that protein expression of BMP6,
noggin and SOST in combination can be used for prediction of
(A) (D) (H)
(B) (E) (I)
(C) (F)
(G)
(J)
Fig. 6. Kaplan–Meier analysis of the prostate cancer patient cohort GSE 21035 in the Gene Expression Omnibus database. (A) bone morphoge-
netic protein 6 (BMP6), (B) noggin and (C) SOST mRNA expression levels were not significantly associated with patient survival in the whole
patient cohort. Noggin mRNA expression was not significantly associated with survival in patients expressing (D) low levels of BMP6 mRNA or (E)
high levels of BMP6 mRNA. (F) SOST mRNA expression was not significantly associated with survival in patients expressing low levels of BMP6.
(G) High levels of SOST mRNA were significantly associated with a shorter survival time in patients expressing high levels of BMP6 mRNA. (H)
Expression levels of noggin and SOST were not significantly associated with survival in patients with low BMP6 expression. (I) Low level expres-
sion of both noggin and SOST was significantly associated with a shorter survival time of patients expressing high levels of BMP6. (J) High BMP6
activity was significantly associated with a shorter survival time in the whole prostate cancer patient cohort.
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prostate cancer metastatic progression and esophageal SCC
patient survival, whereas mRNA expressions of these proteins
in combination can be used for prediction of patient survival
in several types of cancer. Noggin and SOST may play differ-
ent roles in different types of cancer. More importantly, the
combinatorial use of BMP6, noggin and SOST consistently
shows positive correlation with cancer progression.
Deligezer et al.(45) has indicated that the plasma level of
BMP6 mRNA might act as a biomarker to distinguish meta-
static and non-metastatic prostate cancers. Whether the incor-
poration of the mRNA levels of noggin and SOST in plasma
could improve the predictive power of this non-invasive
method warrants further investigation.
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